Xiaofei Wang

Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503)

Nasser K. Altorki, Xiaofei Wang, Dennis A. Wigle et al. · The Lancet Respiratory Medicine · 2018 · 382 citations

Medicine, Oncology, Surgery +17

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Pasi A. Jänne, Xiaofei Wang, Mark A. Socinski et al. · Journal of Clinical Oncology · 2012 · 249 citations

Medicine, Oncology, Pharmacology +14

Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203

Martin J. Edelman, D.K. Watson, Xiaofei Wang et al. · Journal of Clinical Oncology · 2008 · 192 citations · Full text

Medicine, Oncology, Pharmacology +15

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2 : CALGB 151111 (Alliance)

Arnaud Augert, Breanna M. Bates, Min Cui et al. · Journal of Thoracic Oncology · 2016 · 127 citations · Full text

Medicine, Molecular Biology, Oncology +13

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced<i>EGFR</i>-Mutant Non–Small Cell Lung Cancer

Thomas E. Stinchcombe, Pasi A. Jänne, Xiaofei Wang et al. · JAMA Oncology · 2019 · 124 citations · Full text

Medicine, Oncology, Pharmacotherapy +14